In the multicenter DESTINY-Lung01 study, T-DXd was evaluated in 181 patients with HER2-overexpressing NSCLC at 6.4 mg/kg in Cohort 1 and 5.4 mg/kg in Cohort 1A [36]. Here, ERBB2 is linked to non-small cell lung carcinoma.